Shape Therapeutics to Highlight RNA Editing Technology Platform Advancements in Parkinson’s Disease and the Identification of Novel CNS-targeting AAV Variants at the J.P. Morgan 39th Annual Healthcare Conference

• Unveiling of AI-powered RNAfix™ high-throughput discovery platform and application to LRRK2-related Parkinson’s disease
• Identification of CNS-tropic AAVid™ capsids from a non-human primate screening campaign of 1.7 billion unique AAV5 capsid variants
• Presentation by Francois Vigneault, PhD., President and Chief Executive Officer, on January 14^th, 2021 at 11am EST

 

SEATTLE–(BUSINESS WIRE)–#ShapeLife–Shape Therapeutics Inc. (Shape^TX), a next-generation RNA-targeting gene therapy company, announces today the upcoming company presentation at the J.P. Morgan 39^th Annual Healthcare Conference by Francois Vigneault, PhD., President and Chief Executive Officer. The presentation will highlight significant advancements across the Shape^TX technology platforms, including the use of high throughput screening and machine learning to discover RNAfix™ guide-RNAs that enable highly efficient and specific ADAR-mediated RNA editing in Parkinson’s disease. The presentation will also unveil new data from the AAVid™ capsid discovery technology and the discovery of novel CNS-tropic variants from a non-human primate campaign using billions of engineered AAV5 variants.

“RNA is the software of life. We now have next-generation tools to ‘debug’ the source code of genetic diseases like Parkinson’s by targeting RNA directly in the brain. It will be quite exciting to move our RNA editing and tissue-specific AAV delivery technology to the next phase of their development,” said Francois Vigneault, PhD., President and CEO.

About Shape Therapeutics Inc

(Read more…)

Shape Therapeutics is a biotechnology company developing next-generation gene therapy technologies to treat the world’s most challenging diseases. Shape^TX gene therapy platform comprises RNAskip™, RNAfix™, and RNAswitch™ payload technology, next-generation tissue-specific AAVid™ delivery technology, and SquareBio, a solution to scalable gene therapy manufacturing based on industrialization of human stable cell lines. The power of the Shape^TX resides in its core AI discovery platform, where data drives decisions in building technology today to enable gene therapies of tomorrow. Shape^TX is committed to data-driven scientific advancement, passionate people, and a mission of providing life-long cures to patients. Shape Life!

Contacts

Shape Therapeutics Inc.

Investors & Media

John Suliman

CFO & Head of Business Strategy

John@shapetx.com